BioAlliance Pharma Publishes Its Consolidated Half-Year Accounts to June 30, 2008: Increased Revenue and Reinforced Growth via New Licensing Agreements

PARIS--(BUSINESS WIRE)-- BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has published its consolidated accounts to June 30, 2008. Notable features include: